Dr. Vidal on Increasing Access to HER2-Targeted Therapy With Biosimilars

Video

In Partnership With:

Gregory Vidal, MD, PhD, explains how biosimilars could increase access to HER2-targeted therapy.

Gregory Vidal, MD, PhD, assistant professor, Department of Hematology/Oncology, The University of Tennessee Health Science Center, and medical oncologist, West Cancer Center, explains how biosimilars could increase access to HER2-targeted therapy.

Vidal is a proponent of biosimilars because of their potential to increase access to life-saving therapy, he says. Currently, the cost of biologic agents is a barrier to some patients in the United States and overseas. Biosimilars could help bridge this gap in access, says Vidal. However, these agents would likely have the greatest impact in less developed countries where cost is prohibitive, adds Vidal.

In breast cancer, access to HER2-targeted therapy is critical. Biosimilars could increase competition and lower the cost of therapy, which would be a tremendous gain for patients with HER2-positive breast cancer. As long as biosimilars demonstrate similar efficacy to the originator biologic—and all agents that have been approved to date have done so—these agents should be embraced by the medical community, concludes Vidal.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute